

SHUKRA PHARMACEUTICALS LTD.

08th November, 2023

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai - 400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Statement of deviation or variation in the use of proceeds of Rights Issue
Ref: Regulation 32 of SEBI (Listing Obligations and Disclosures Requirements)
Regulation, 2015.

Pursuant to Regulation 32 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015, We hereby confirm that there is no deviation and/or variation in the utilization of proceeds, from the object mentioned in the letter of offer dated February 01, 2023 for Right Issue of partly paid-up equity shares in which ₹ 8.00/- each (Including share premium of ₹ 4.00) was payable on Second and Final Call Money. It is further confirmed that the proceeds of Second and Final Call Money for 92,55,046 Partly Paid-up equity shares on a Right basis on during the Quarter ended September 30, 2023, have been fully utilized.

A statement of deviation, stating that there is no deviation or variation in the utilization of these proceeds, duly reviewed by the Audit Committee, is attached herewith as Annexure-A.

This is for your kind information and record.

Thanking You

Yours faithfully

For, Shukra Pharmaceuticals Limited

DIN:0836893

Bhoome Patel

Encl.: a/a

CIN: L24231GJ1993PLC019079





Statement of Deviation / Variation in utilization of funds raised under Right issue - Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Name of Listed Entity	Shukra Pharmaceuticals Limited			
Mode of Fund Raising	Right Issue of Partly Paid-Up Equity Shares			
Date of Raising Fund	July 12, 2023 (Being Second and Final Call Progression Date)			
Amount Raised	₹ 7.40 Crores (on Second and Final Call Money) (Total amount raised under Rights issue is ₹ 18.78 Crores)			
Report filed for Quarter and Year Ended	September 30, 2023			
Monitoring Agency	NA			
Monitoring Agency Name, If Applicable	NA			
Is there any Deviation / Variation in use of funds raised	No			
If yes, Whether the same is pursuant to change in terms of a contract or object, which was approved by the shareholders	NA			
If Yes, Date of Shareholder approval	NA			
Explanation for Deviation / Variation	NA			
Comments of Audit Committee after review	No Comments			
Comments of auditors if any	No Comments			



CIN: L24231GJ1993PLC019079



Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	*Original Allocation	Modified allocation, if any	Funds Utilized	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Existing and incremental working capital requirement of our company	Nil	₹ 5.55 Crores	Nil	₹ 5.55 Crores	Nil	No deviation
General Corporate Purposes	Nil	₹ 1.85 Crores	Nil	₹ 1.85 Crores	Nil	No deviation

^{*}For the Second and Final Call Money of Rs. 8.00 each (Including premium of Rs. 04).

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised; or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or

(c) Change in terms of a contract referred to in the fundraising document i.e., prospectus, letter of offer, etc

For, Shukra Pharmaceuticals Limited

Director

DIN:0836893

Date: 08/11/2023 Place: Ahmedabad

CIN: L24231GJ1993PLC019079